Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the Risk of Diabetic Retinopathy Between Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus in Japan: A Retrospective Analysis of Real-World Data.
Koshizaka M, Tatsumi T, Kiyonaga F, Kosakai Y, Yoshinaga Y, Shintani-Tachi M. Koshizaka M, et al. Among authors: kosakai y. Diabetes Ther. 2024 Nov;15(11):2401-2416. doi: 10.1007/s13300-024-01649-9. Epub 2024 Sep 30. Diabetes Ther. 2024. PMID: 39347896 Free PMC article.
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
Kashiwagi A, Shoji S, Kosakai Y, Yoshinaga Y, Rokuda M. Kashiwagi A, et al. Among authors: kosakai y. J Diabetes Investig. 2024 Mar;15(3):374-387. doi: 10.1111/jdi.14123. Epub 2023 Dec 19. J Diabetes Investig. 2024. PMID: 38112598 Free PMC article.
Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y. Kashiwagi A, et al. Among authors: kosakai y. J Diabetes Investig. 2022 Jul;13(7):1175-1189. doi: 10.1111/jdi.13785. Epub 2022 Apr 9. J Diabetes Investig. 2022. PMID: 35243799 Free PMC article.
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Kashiwagi A, Shoji S, Kosakai Y, Koga T, Asakawa K, Rokuda M. Kashiwagi A, et al. Among authors: kosakai y. J Diabetes Investig. 2023 Mar;14(3):404-416. doi: 10.1111/jdi.13952. Epub 2022 Dec 14. J Diabetes Investig. 2023. PMID: 36515129 Free PMC article.
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Satomi H, Kosakai Y, Kawamuki K. Kashiwagi A, et al. Among authors: kosakai y. J Diabetes Investig. 2016 Jul;7(4):544-54. doi: 10.1111/jdi.12471. Epub 2016 Mar 1. J Diabetes Investig. 2016. PMID: 27181576 Free PMC article. Clinical Trial.
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A, Sakatani T, Nakamura I, Akiyama N, Kazuta K, Ueyama E, Takahashi H, Kosakai Y. Kashiwagi A, et al. Among authors: kosakai y. Endocr J. 2018 Jul 28;65(7):693-705. doi: 10.1507/endocrj.EJ17-0491. Epub 2018 May 29. Endocr J. 2018. PMID: 29848902 Free article. Clinical Trial.
166 results